Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 06275-0188002	Application No. 10/665,240	
	closure Statement	Applicant Tommy Ekstrom		
(Use several sheets if necessary)		Filing Date	Group Art Unit	
(37 CFR 81 98(b))		September 19, 1993	1617	

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	5,674,860	10/2007	Carling et al.			
	A2	5,972,919	10/1999	Carling et al.			
	A3	6,030,604	02/2000	Trofast			
	A4	6,227,862	08/2001	Giardina et al.			
	A5	6,598,603	07/2003	Andersson et al.			

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	A6	9703407-8		Sweden				
	A7	EP 1 014 993	07/05/2000	Europe				

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
	A8	Additive effects of Budesonide and Formoterol in Reducing Severe Asthma Exacerbations Over 12 Months, O'Byrne et al. on behalf of international study group and Astra Draco AB Lund Sweden		
	A9	"American Thoracic Society: Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease," Am. J. Respir. Care Med. 152:S77-S121 (1995)		
	A10	"Analysis of DIN-LINK Co-prescription Records for Inhaled Steroids and Long-Acting Beta Agonists in the Period 1990-1998" pages 1-2, appendices A and B		
	A11	"Atemstillstand" Pschyrembel Klinisches Wörtebuch (2002) (in German)		
	A12	Auffarth et al., "Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease" Thorax 46:372-377 (1991)		
	A13	Barnes, "Inhaled steroids in COPD" The Lancet 351:766-767 (1998)		
	A14	Barnes et al., "Chronic obstructive pulmonary disease: molecular and cellular mechanisms," Eur. Respir. J. 22:672-688 (2003)		
	A15	Basic Reference Manual, vol. 1, revised ed. of 1988, issued by IMS International		
	A16	Boyd et al., "An Evaluation of Salmeterol in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)," Eur. Resp. J. 10:815-821 (1997)		
	A17	"Bronchodilators and anti-inflammatories," Monthly Index of Medical Specialities (MIMS) 242-256 (09/1997)		
	A18	Buist, "Definitions," in Asthma and Chronic Obstructive Pulmonary Disease, Barnes et al. eds., Acad. Press, pp. 3-6 (2002)		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant	t in conformance and not considered. Include copy of this form with

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0188002	Application No. 10/665,240
	closure Statement	Applicant Tommy Ekstrom	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date September 19, 1993	Group Art Unit 1617

Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	A19	Burge et al. "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial," British Med. J. 320:1297-1303 (2000)					
	A20	Calverley et al., "Maintenance therapy with budesonide and formoterol in chronic obstructive ulmonary disease," Eur. Respir. J. 22:912-919 (2003)					
	A21	Cazzola et al., "Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease", Pulmonary Pharmacology, 1994, 7/2, pages 103-107.					
	A22	Compendium Suisse des Medicaments, 15 th Ed. 1997/1998, Ed. Grand Public, compiled June 1996, pages 2-3, 419-429, 866 (in French).					
	A23	and 1635-1636 (in French).					
	A24	C. Wyser et al., "Neue Aspekte in der Behandlung des Asthma bronchiale und chronisch obstruktiver Lungenkrankheiten", 1997, Schweiz Med Wochenschr, Volume 127, pages 885-890.					
	A25	Davies et al., "Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease," Q. J. Med. 92:395-400 (1999)					
	A26	Declaration of Professor N.B. Pride dated August 4, 2004					
	A27	pages 4-9 (1989).					
	A28	Stamford, CT: Appleton and Lange (1997)					
	A29	Dompeling et al., "Slowing the deterioration of Asthma and Chronic Obstructive Pulmonary Disease Observed during Bronchodilator Therapy by Adding Inhaled Corticosteroids," Ann. Intern. Med. 118(10):770-778 (1993)					
	A30	Engel et al., "A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis" Eur. Respir. J. 2:935-939 (1989)					
	A31	Fabbri et al., "Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update" Eur. Respir. J. 22:1-2 (2003)					
	A32	Flenley, "Chronic Obstructive Pulmonary Disease," Disease-A-Month 34:549-599 (1988)					
	A33	"Foradil" Compendium Suisse des Medicaments, Supplement 1a pages 7-8 (1991) (in French)					
	A34	"Foradil," Compendium Suisse des Medicaments, 15th Ed. 1997/1998, Ed. Grand Public, compiled June 1996, pages 419-420, 866 (in French)					
	A35	"Foradil," Compendium Suisse des Medicaments, 18th Ed. 1997, compiled June 1996, pages 849-850 and 1635 (in French)					
	A36	"Foradil" Patient information leaflet, published by IKS, Switzerland (12/1990) (in French)					
	A37	"Foradil" MIMS-Monthly Index of Medical Specialties January 10 (1996)					
	A38						
	A39	"GOLD: Global Initiative for Chronic Obstructive Lung Disease," Executive Summary; National Institutes of Health, National Heart Lung and Blood Institute, NIH Publication No. 2701A, pages 1-30 (03/2001)					

Date Considered					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with					
1					

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0188002	Application No. 10/665,240	
	closure Statement oplicant	Applicant Tommy Ekstrom		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date September 19, 1993	Group Art Unit 1617	

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
militar	A40	"GOLD: Global Initiative for Chronic Obstructive Lung Disease; Global Strategy for the Diagnosis,
	A41	Jackevicius et al., "Prehospitialization Inhaled Cortiscoteroid Use in Patients With COPD or Asthma" Chest 111:296-302 (1997)
	A42	136 (1998)
	A43	Keatings et al., "Effects of Inhaled and Oral Glucocorticoids on Inflammatory Indices in Asthma and COPD" Am. J. Respir. Crit. Care Med. 155:542-548 (1997)
	A44	Kerstjens et al., "A Comparison of Bronchodilator Therapy with or without Inhaled Corticosteroid Therapy for Obstructive Airways Disease," New Eng. J. Med. 327:1413-1419 (1992)
	A45	Leff et al., "Therapeutic Regimens in Chronic Obstructive Pulmonary Disease," Pulmon. Crit. Care Pharmacol. Therapeut. Ch. 86:837-844 (1996)
	A46	Minutes of the May 6, 2008 oral proceedings before the European Patent Office Technical Board of Appeal in the opposition against EP 1014993 (4 pages)
	A47	Nederlands Tijdschrift voor Geneeskunde "Opportunistic lung infection in patients with chronic obstructive pulmonary disease", 1996 140/2 pages 94-98 ISSN: 0028-2162 CODEN: NET JAN
	A48	New Ethicals Catalogue, December 1990, No. 3, p. 50
	A49	Niewoehner et al., "Effect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease" New Eng. J. Med. 340(25):1941-1947 (1999)
	A50	Norman, "COPD: New Developments and Therapeutic Opportunities" <i>Drug News Perpect</i> . 11(7):431-437 (1998)
	A51	Pauwels et al., "Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking" N. Eng. J. Med. 340:1948-1953 (1999)
	A52	Pauwels, "COPD: The Scope of the Problem in Europe" Chest 117:332S-335S (2000)
	A53	Pearson et al., "British Thoracic Society Guidelines for Treatment of COPD" Thorax 52 (Suppl. 5):S1-S28 (1997)
	A54	Postma et al., "Rationale for the Dutch Hypothesis* Allergy and Airway Hyperresponsiveness as
	A55	Postma, "Inhaled therapy in COPD: what are the benefits?" Respiratory Medicine 85:447-449 (1991)
	A56	"Pulmicort" ABPI Data Sheet Compendium, p. 146-147 (1995/1996)
	A57	Respir. J. 22:874-875 (2003)
	A58	Renkema et al., "Effects of long-term treatment with corticosteroids in COPD.", Chest, 1996, Vol. 109, No. 5, abstract. AN 1996: 325104.
	A59	Renkema et al. "Key to the World's Chemical Literature", Vol. 126, No. 20 (1997), CA (Chemical Abstracts) No. 259329
	A60	Roberts et al., "Which patients are prescribed inhaled anti-asthma drugs?" <i>Thorax</i> 49(11):1090-1095 (1994)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 06275-0188002	Application No. 10/665,240	
	closure Statement oplicant	Applicant Tommy Ekstrom		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date September 19, 1993	Group Art Unit 1617	

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	A61	Sauders Manual of Medical Practice. Rakel 1996.	
	A62	Schultze-Werninghaus, "Multicenter 1-Year Trial on Formoterol, a New Long-Acting β ₂ -Agonist, in Chronic Obstructive Airway Disease," <i>Lung</i> Suppl:83-89 (1990)	
	A63	(COPD), Eur. Respir. J. 8:1398-1420 (1995)	
	A64	Soriano et al., "The Proportional Venn Diagram of Obstructive Lung Disease* Two Approximations From the United States and the United Kingdom", Chest 124: 474-481 (2003).	
	A65	Soriano et al., "Inhaled Corticosteroids with/Without Long-Acting b-Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients," Am. J. Respir. Medic. 2:67-74 (2003)	
	A66	Stalenheim et al., "Efficacy and Tolerance of a 12-Week Treatment with Inhaled Formoterol in Patients with Reversible Obstructive Lung Disease," Respiration 61:305-309 (1994)	
	A67	Statutory Declaration of Charles Richard William Beasley	
	A68	Stedman's Medical Dictionary, 25th ed., Baltimore: Williams and Wilkins; page 428	
	A69	Szafranski et al., "Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease" Eur. Respir. J. 21:74-81 (2003)	
	A70	The Merck Manual, sixteenth Edition, 1992, pages 658-659	
	A71	Treschel, AM Conference Report, A new long-acting beta-stimulator	
	A72	Eur. Respir. J. 9:1969-1972 (1996)	
	A73	Van Andel et al., "Analysis of Inhaled Corticosteroid and Oral Theophylline Use Among Patients With Stable COPD from 1987 to 1995" <i>Chest</i> 115:703-707 (1999)	
	A74	Vestbo et al., "Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial," <i>Lancet</i> 353:1819-1823 (1999)	
	A75	53(Suppl.2), S15-S19 (1998).	
	A76	(1992)	
	A77	(1995)	
	A78	Written decision of the European Patent Office Technical Board of Appeal in the opposition against EP 1014993, dated May 6, 2008 (17 pages).	

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				